---
canonical_url: https://www.stockexpertai.com/earnings/lh
last_updated: 2026-05-09T13:55:50.926Z
---

# Labcorp Holdings Inc. (LH) Q4 FY2026 Earnings Preview

> This content was automatically generated with FMP live data + Q1 FY2026 earnings call transcript. Generated: 2026-05-09T13:55:50.495Z. Educational tool, not investment advice.

---

## Quick Summary

| Field | Value | Source |
|---|---|---|
| Price | $254.12 (▼ -1.52%) | fmp:quote |
| Market Cap | $20.8B | fmp:profile |
| 52w range | $239.67 – $293.72 | fmp:quote |
| Earnings | Thu 23 Jul | fmp:earnings-history |
| EPS estimate | $4.78 (+10% YoY) | fmp:earnings-estimate |
| Revenue estimate | $3.7B | fmp:earnings-estimate |
| Beat streak | 8/4 | fmp:earnings-history |
| Rating | B+ (overall 3/5) | fmp:ratings |
| Analyst median target | $300 (+18.1% upside) | fmp:price-target-consensus |
| MoonshotScore | 36/100 | derived |
| Council | 2/6 bullish | derived |
| Munger verdict | Fairly Valued | derived |

## Labcorp Holdings Inc. — Q4 FY2026 Expectations

Q4 consensus: revenue <strong data-source="fmp:earnings-estimate" data-field="estimates.next.revenueAvgLabel">$3.7B</strong><sup class="cite" data-source="fmp:earnings-estimate" data-field="estimates.next.revenueAvg" title="FMP est">[FMP est]</sup>, EPS <strong data-source="fmp:earnings-estimate" data-field="estimates.next.epsAvg">$4.78</strong><sup class="cite" data-source="fmp:earnings-estimate" data-field="estimates.next.epsAvg" title="FMP est">[FMP est]</sup>. 8 consecutive quarters of beat<sup class="cite" data-source="fmp:earnings-history" data-field="earnings.beatStreakCount" title="FMP earnings">[FMP earnings]</sup>.

## Quick Take

**Score:** B+ · **Stance:** BUY · **Council:** 2/6 · **Moonshot:** 36

= MoonshotScore <strong>36</strong><sup class="cite" data-source="derived" data-field="moonshot.score" title="9-pillar formula">[9-pillar formula]</sup> + Council <strong>2/6</strong><sup class="cite" data-source="derived" data-field="council.bullishCount" title="6-lens rule">[6-lens rule]</sup>. Form 4: 0 transactions<sup class="cite" data-source="fmp:insider-trading" data-field="insider.txCount" title="FMP Form 4">[FMP Form 4]</sup>.

## Watchlist (5 metrics)

### 1. Biopharma Growth

Biopharma Laboratory Services (BLS) revenue grew by 8.2%, with central labs driving the growth.

> "Biopharma Laboratory Services revenue grew to $781 million, up 8.2% compared to last year, which includes a 5.5% benefit from foreign currency translation."
> — Julia Wang, CFO, Investor Focus · Q1 FY2026

### 2. Revenue Growth

Labcorp had a strong start to the year, achieving a revenue increase of 5.8% in the first quarter.

> "In the first quarter, enterprise revenue grew 5.8% and enterprise adjusted operating margin expanded more than 30 basis points to 14.4%."
> — Julia Wang, CFO, Investor Focus · Q1 FY2026

### 3. Fy26 Guidance Increase

Labcorp is raising its revenue and earnings per share (EPS) expectations for 2026.

> "We are raising the midpoint of the enterprise revenue range by approximately $30 million and the midpoint of the EPS range by $0.13."
> — Julia Wang, CFO, Expectation / Guide · Q1 FY2026

### 4. Diagnostics Growth

Diagnostic Laboratories delivered another strong quarter with 5% revenue growth.

> "Diagnostic Laboratories delivered another strong quarter with 5% revenue growth to $2.8 billion."
> — Julia Wang, CFO, Investor Focus · Q1 FY2026

### 5. Bls Backlog

The BLS segment ended the quarter with a backlog of $8.6 billion, and we expect approximately $2.7 billion to convert into revenue over the next 12 months.

> "Our BLS segment ended the quarter with a backlog of $8.6 billion, and we expect approximately $2.7 billion to convert into revenue over the next 12 months."
> — Julia Wang, CFO, Investor Focus · Q1 FY2026


## MoonshotScore Pillars

| Pillar | Score | Level | Evidence |
|---|---|---|---|
| Revenue Growth | 0.0 | weak | Q1 vs Q2: growth slowing (+0.3%, below threshold) |
| Gross Margin | 3.0 | weak | Q1: low margin (26.5%, capital-intensive or commodity) |
| Operating Leverage | 1.0 | weak | op margin average (10.9%) |
| Cash Runway | 6.0 | medium | FCF positive but absorbed ($0.1B vs $0.1B CapEx) |
| R&D Intensity | 3.0 | weak | low R&D investment (0.0%, weak innovation) |
| Price Momentum | 4.0 | medium | RSI 37.7 weak momentum, 50d below |
| News Sentiment | 8.0 | strong | strong buy consensus (75%) |

**Formula:** sum(pillar.score) / (count * 10) * 100. Each pillar deterministic from FMP. Source maps in pillar.formula.

## Council (7-Lens)

| Name | Stance | Context |
|---|---|---|
| Ray Dalio | bull | macro · target upside +18.1% |
| Ken Griffin | bear | flow · 50d MA below |
| Jim Simons | neutral | quant · RSI 38 |
| Klarman | neutral | value · target upside +18.1% |
| Buffett | bull | quality · ROE score 4/5 |
| Munger | neutral | valuation · target upside +18.1% |

**Formula:** Each lens uses deterministic rule on bundle data. Logged in member.contextTr.

## Munger Lens

- **Verdict:** Fairly Valued
- **Financial Health:** Moderate
- **Margin of Safety:** Moderate
- **Interest Coverage:** Adequate
- **ROIC vs WACC:** Healthy

**Formula:** verdict=upside>25?Undervalued:>0?Fairly Valued:Overvalued. Each lens deterministic from FMP ratings + priceTarget.

## Technical Levels

- **RSI(14):** 37.7 — momentum zayıf — oversold yakınında değil ama alıcı baskısı az
- **50d MA:** $267 — hisse %4.9 altında — kısa vadeli direnç
- **200d MA:** $269 — hisse %5.5 altında — uzun vadeli baskı
- **Volume (10d):** -36%

## Past Performance (4 Quarters)

| Quarter | EPS Actual | EPS Estimate | Result | Reaction |
|---|---|---|---|---|
| Q2 FY25 | $4.35 | $4.17 | BEAT | -1.0% |
| Q3 FY25 | $4.18 | $4.13 | BEAT | -4.4% |
| Q4 FY25 | $4.07 | $3.95 | BEAT | +0.8% |
| Q1 FY26 | $4.25 | $4.09 | +3.9% EPS | -0.4% |

Q1 (April 30, 2026): EPS $4.25 vs $4.09 est<sup class="cite" data-source="fmp:earnings-history" data-field="earnings.history.0" title="FMP">[FMP]</sup>, +3.9% beat. D+1 movement: -0.4%<sup class="cite" data-source="fmp:earnings-history" data-field="earnings.timeline.3.reactionLabel" title="FMP D+1">[FMP D+1]</sup>. Decline despite beat — market reacted to guidance, not numbers.

## 3 Scenarios

### Scenario A · Beat
**Q4 EPS > $4.78 + CapEx discipline**

Threshold: EPS > $4.78<sup class="cite" data-source="fmp:earnings-estimate" data-field="estimates.next.epsAvg">[FMP est]</sup>.

Target: Break above median target $300<sup class="cite" data-source="fmp:price-target-consensus" data-field="priceTarget.median">[FMP target]</sup>; high target $334<sup class="cite" data-source="fmp:price-target-consensus" data-field="priceTarget.high">[FMP]</sup> upper bound.

### Scenario B · In-Line
**EPS ≈ $4.78 + CapEx < $121.0M**

Threshold: EPS ≈ $4.78<sup class="cite" data-source="fmp:earnings-estimate" data-field="estimates.next.epsAvg">[FMP est]</sup>, Q4 CapEx < $121.0M<sup class="cite" data-source="fmp:cashflow" data-field="cashflow.qPrev.capexLabel">[FMP]</sup>.

Target: Consolidation in the band between current $254<sup class="cite" data-source="fmp:quote" data-field="quote.price">[FMP]</sup> and median $300<sup class="cite" data-source="fmp:price-target-consensus" data-field="priceTarget.median">[FMP]</sup>.

### Scenario C · Miss
**EPS < $4.64 or CapEx ≥ $121.0M**

Threshold: EPS < $4.64<sup class="cite" data-source="fmp:earnings-estimate" data-field="estimates.next.epsAvg">[FMP est×0.97]</sup>.

Target: Current $254 below SMA200 $269<sup class="cite" data-source="fmp:technical" data-field="technical.sma200">[FMP]</sup>, if rejection continues, $229<sup class="cite" data-source="derived" data-field="technical.sma200" data-formula="round(sma200*0.85)">[derived]</sup> support activates.

## Risk Notes

### Primary segment below threshold
Q1: EPS $4.25 vs $4.09 beat<sup class="cite" data-source="fmp:earnings-history" data-field="earnings.history.0" title="FMP">[FMP]</sup>, stock -0.4% D+1<sup class="cite" data-source="fmp:earnings-history" data-field="earnings.timeline.3.reactionLabel" title="FMP">[FMP]</sup>.

### Backlog concentration
No RPO/backlog concentration disclosed in Q1 earnings call.

### Insider trading
Form 4 data is marked in the table — this page does not generate assumptions for this stock.

| Executive | Action | Amount | Date |
|---|---|---|---|


**Net:** — (0 transactions · 0 sells · 0 buys) · Q1 FY26

### CapEx shock
Q1 CapEx $121.0M<sup class="cite" data-source="fmp:cashflow" data-field="cashflow.qPrev.capexLabel" title="FMP cashflow">[FMP cashflow]</sup>. Q1 op margin 10.9%<sup class="cite" data-source="fmp:income" data-field="income.quarters.0.operatingMargin" title="FMP op margin">[FMP op margin]</sup> — this level in Q4 is sensitive to CapEx revision risk.

## Wall Street Consensus

- **Median target:** $300 (+18.1% upside vs current $254)
- **High / Low:** $334 / $300
- **Buy / Hold / Sell:** 15 / 5 / 0
- **Analyst count:** 4 (last quarter), 33 all-time

## Additional Transcript Insights

### 1. revenue_growth

**Claim:** Labcorp had a strong start to the year, achieving a revenue increase of 5.8% in the first quarter.

**Evidence (transcript):** "In the first quarter, enterprise revenue grew 5.8% and enterprise adjusted operating margin expanded more than 30 basis points to 14.4%."

**Numbers:** 5.8%, 30, 14.4%

### 2. diagnostics_growth

**Claim:** Diagnostic Laboratories delivered another strong quarter with 5% revenue growth.

**Evidence (transcript):** "Diagnostic Laboratories delivered another strong quarter with 5% revenue growth to $2.8 billion."

**Numbers:** 5%, $2.8 billion

### 3. biopharma_growth

**Claim:** Biopharma Laboratory Services (BLS) revenue grew by 8.2%, with central labs driving the growth.

**Evidence (transcript):** "Biopharma Laboratory Services revenue grew to $781 million, up 8.2% compared to last year, which includes a 5.5% benefit from foreign currency translation."

**Numbers:** $781 million, 8.2%, 5.5%

### 4. bls_backlog

**Claim:** The BLS segment ended the quarter with a backlog of $8.6 billion, and we expect approximately $2.7 billion to convert into revenue over the next 12 months.

**Evidence (transcript):** "Our BLS segment ended the quarter with a backlog of $8.6 billion, and we expect approximately $2.7 billion to convert into revenue over the next 12 months."

**Numbers:** $8.6 billion, $2.7 billion, 12

### 5. fy26_guidance_increase

**Claim:** Labcorp is raising its revenue and earnings per share (EPS) expectations for 2026.

**Evidence (transcript):** "We are raising the midpoint of the enterprise revenue range by approximately $30 million and the midpoint of the EPS range by $0.13."

**Numbers:** $30 million, $0.13, 2026


---

*Data source: FMP (live query, 2026-05-09), Q1 FY2026 earnings call transcript (Translated to EN with Gemini 2.0 Flash). Educational tool, not investment advice.*